Abstract 370P
Background
LYMPHA is a relatively new surgical technique that dramatically reduces the incidence of lymphedema following axillary node clearance in breast cancer patients. The technique identifies dominant lymph vessels draining the arm with the aid of dye and, following clearance of the axillary nodes, anastomosing lymphatic vessels to a branch of the axillary vein to enable free drainage of lymphatic fluid. Not currently widely available to breast cancer patients in the UK, this simple surgical procedure carried out at the time of axillary node clearance has been shown to reduce the incidence of lymphedema from 25% to 4%. We report on the establishment of a LYMPHA service at a major London Plastics Centre and first 2 years of its outcomes.
Methods
Suitable patients were referred to plastics by the breast surgery team and seen preoperatively to discuss LYMPHA. Upon agreeing to the procedure, pre-operative measurements of arm volume and arm bioimpedance were completed as well as screening questionnaires on symptoms of lymphedema. Subsequent to the procedure the two measurements and the questionnaires were repeated at 1, 3, 6, 12 and 24 month intervals.
Results
Of 16 patients that have undergone the LYMPHA procedure 0 have experienced signs or symptoms of lymphedema to date. One patient suffered temporary swelling of the arm 1-month post-op which subsequently resolved. No patients have suffered any complications relating to LYMPHA. 1 patient withdrew due to metastatic disease recurrence. The patients enrolled have been followed up for between 3-23 months with a current mean follow up time of 12.61 months.
Conclusions
Our findings thus far support current evidence that LYMPHA surgery is both safe and effective in reducing the incidence of lymphedema. This pilot study is currently being developed into an RCT which will add to the evidence base of this relatively niche area of plastic surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Presenter: Miguel Martin Jimenez
Session: Poster session 03
414P - Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Presenter: Isabella Michelon
Session: Poster session 03
415P - Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Presenter: Linda Cucciniello
Session: Poster session 03
416P - Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Presenter: Sandeep Sehdev
Session: Poster session 03
417P - New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Presenter: Viola Cogliati
Session: Poster session 03
418P - Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Presenter: Qingyuan Zhang
Session: Poster session 03
419P - Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
Presenter: Elaine Walsh
Session: Poster session 03
421P - Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Presenter: Takayuki Iwamoto
Session: Poster session 03
422P - UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Presenter: Georgina Gullick
Session: Poster session 03
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03